Salestools LogoSalestools
Salestools AI-agenter
Lösningar
Resurser
Företag
Priser
Salestools Logo

Salestools

#1 AI-agent för säljteam och Go-to-Market-team. Sälj mer, snabbare, med mindre ansträngning.

Produkt

  • AI-säljagenter
  • Intentionsdata
  • Teknologidata
  • Besöksspårning
  • Medpilot
  • Social Försäljning

Lösningar

  • Kundservice
  • E-handel
  • SaaS
  • Företag
  • Småföretag

Resurser

  • Rapporten
  • Dokumentation
  • API-referens
  • Hjälpcenter
  • Blogg
  • Fallstudier
  • Webbinarier

Företag

  • Om oss
  • Karriärer
  • Press
  • Kontakt
  • Partners

Våra kontor

  • New York, HQ
  • Bukarest, AI-forskningslabb
  • Zug, Schweiz

© 2026 Salestools. Alla rättigheter förbehållna.

Datavillkor och SäkerhetSekretesspolicyAnvändarvillkorAcceptable Use
Alla system fungerar
Salestools LogoSalestools
Salestools AI-agenter
Lösningar
Resurser
Företag
Priser
Back to Reports
Fundraising

Arthrosi Therapeutics

Arthrosi Therapeutics Raises $153M in Series E

San Diego, CAOctober 8, 20252 min read
Employees
120+

Arthrosi Therapeutics Raises $153M in Series E


Arthrosi Therapeutics has successfully raised $153M in a Series E at a $800M valuation led by New Enterprise Associates, RA Capital.


Company Overview


Arthrosi Therapeutics is a Biotech company headquartered in San Diego, CA, founded in 2019 with 120+ employees.


Developing next-generation gout treatment drug for chronic conditions


Fundraising Details


  • Amount Raised: $153M
  • Round Type: Series E
  • Valuation: $800M
  • Date: 2025-10-08
  • Investors: New Enterprise Associates, RA Capital

About Arthrosi Therapeutics


Developing next-generation gout treatment drug for chronic conditions The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: San Diego, CA
  • Founded: 2019
  • Team Size: 120+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Arthrosi Therapeutics's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Arthrosi Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $800M valuation marks an important milestone for Arthrosi Therapeutics, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Arthrosi Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2025-10-08. For more information about Arthrosi Therapeutics, visit their headquarters at San Diego, CA.

Company Info

Headquarters
San Diego, CA
Founded
2019
Team Size
120+

Topics

Fundraising(2912)BiotechSeries EArthrosi Therapeutics

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free